Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

General Patient-Reported Outcome Measure Tools Non-Reflective of AL Amyloidosis Quality of Life (QoL): A Systematic Literature Review

Sotirios Bristogiannis, Charalampia Kyriakou, Ashutosh Wechelaker, Brendan Wisniowski, Shameem Mahmood, Sajitha Sachchithanantham

Blood (2021) 138 (Supplement 1): 5007.

https://doi.org/10.1182/blood-2021-147021

Published: 2021

Journal Articles

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Ananth Sathyanath, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Sajitha Sachchithanantham, MBBS, BSc, FRCPath, Shameem Mahmood, Ana Martinez-Naharro, Marianna Fontana, Carol Whelan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137036

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

The genomic landscape of plasma cells in systemic light chain amyloidosis

Blood (2018) 132 (26): 2775–2777.

https://doi.org/10.1182/blood-2018-08-872226

Published: 2018

Includes: Supplemental data

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Richa Manwani, MBBS, FRCPath, BSc, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2018-99-116688

Published: 2018

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (7): 761–764.

https://doi.org/10.1182/blood-2018-04-846493

Published: 2018

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, BSc,FRCPath,MBBS,MRCP, Marianna Fontana, Carol Whelan, Candida Quarta, Thirusha Lane, Helen Lachmann, Julian Gillmore, Philip Hawkins, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2017) 130 (Supplement 1): 1816.

https://doi.org/10.1182/blood.V130.Suppl_1.1816.1816

Published: 2017

Journal Articles

Natural history and outcome of light chain deposition disease

Rabya H. Sayed, Ashutosh D. Wechalekar, Janet A. Gilbertson, Paul Bass, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Ketna Patel, Carol J. Whelan, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore

Blood (2015) 126 (26): 2805–2810.

https://doi.org/10.1182/blood-2015-07-658872

Published: 2015

Includes: Supplemental data

Journal Articles

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

Giovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, Julian Gillmore, Andrea Foli, Helen Lachmann, Marco Basset, Philip Hawkins, Giampaolo Merlini, Ashutosh D. Wechalekar

Blood (2015) 126 (5): 612–615.

https://doi.org/10.1182/blood-2015-01-620302

Published: 2015

Includes: Supplemental data

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis

Giovanni Palladini, MD PhD, Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Paolo Milani, MD, Julian D Gillmore, Andrea Foli, MD, Philip N Hawkins, Giampaolo Merlini, MD, Ashutosh D Wechalekar

Blood (2014) 124 (21): 305.

https://doi.org/10.1182/blood.V124.21.305.305

Published: 2014

Journal Articles

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Eileen M Boyle, MD, Brian A Walker, PhD, Dorota Rowczienio, MSc, Christopher P Wardell, PhD, Alexander Murison, PhD, Aneta Mikulasova, M.Sc., Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Anna Baginska, Shameem Mahmood, MRCP. FRCPath, Julian D Gillmore, Helen J Lachmann, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci, Xavier Leleu, MD PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Ashutosh Wechalekar, MDFRCPath

Blood (2014) 124 (21): 726.

https://doi.org/10.1182/blood.V124.21.726.726

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

NARROW

General Patient-Reported Outcome Measure Tools Non-Reflective of AL Amyloidosis Quality of Life (QoL): A Systematic Literature Review

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

The UK Experience of Renal Transplantation in AL Amyloidosis

The genomic landscape of plasma cells in systemic light chain amyloidosis

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Natural history and outcome of light chain deposition disease

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only